Martingale Asset Management L P Buys New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Martingale Asset Management L P acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 87,077 shares of the biopharmaceutical company's stock, valued at approximately $1,731,000. Martingale Asset Management L P owned 0.07% of Catalyst Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CPRX. FORA Capital LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at about $516,000. Cynosure Group LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $353,000. BNP Paribas Financial Markets raised its holdings in Catalyst Pharmaceuticals by 206.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 153,250 shares of the biopharmaceutical company's stock worth $3,047,000 after purchasing an additional 103,186 shares during the last quarter. Quantbot Technologies LP bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $151,000. Finally, FMR LLC raised its holdings in Catalyst Pharmaceuticals by 24.3% during the 3rd quarter. FMR LLC now owns 98,580 shares of the biopharmaceutical company's stock worth $1,960,000 after purchasing an additional 19,270 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on CPRX. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective for the company. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 9th. Finally, Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and an average target price of $31.14.

Catalyst Pharmaceuticals Trading Up 2.1 %

Shares of Catalyst Pharmaceuticals stock traded up $0.46 on Monday, reaching $22.53. 1,096,556 shares of the company were exchanged, compared to its average volume of 1,186,761. Catalyst Pharmaceuticals, Inc. has a one year low of $13.00 and a one year high of $24.27. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.40 and a beta of 0.75. The company has a 50-day moving average of $21.26 and a 200 day moving average of $18.79.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.